Patents by Inventor João Conde

João Conde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPV2 Antagonists
    Publication number: 20220152006
    Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2).
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Inventors: Gonçalo BERNARDES, Tiago RODRIGUES, João CONDE, Charlotte BAKER
  • TRPV2 antagonists
    Patent number: 11273152
    Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2). Methods of treatment of conditions that are characterised by TRPV2 expression using Piperlongumine compounds and Piperlongumine compounds for use in such treatments are provided.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 15, 2022
    Assignee: Instituto de Medicina Molecular João Lobo Antunes
    Inventors: Goncalo Bernardes, Tiago Rodrigues, João Conde, Charlotte Baker
  • TRPV2 Antagonists
    Publication number: 20200253943
    Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 13, 2020
    Inventors: Goncalo Bernardes, Tiago Rodrigues, João Conde, Charlotte Baker
  • Micro-RNA Delivery Compositions, Devices, and Methods
    Publication number: 20190185854
    Abstract: Provided herein are compositions that include a metal nanoparticle functionalized with a miRNA and a targeting molecule. The compositions may be used to prevent or reduce the rate of metastasis of cancer cells. The compositions also may include a drug, such as a chemotherapeutic agent. The compositions also may include a hydrogel in which the metal nanoparticles are dispersed. Methods of miRNA and/or drug delivery and kits also are provided.
    Type: Application
    Filed: June 23, 2017
    Publication date: June 20, 2019
    Inventors: Natalie Artzi, João Conde, Noam Shomron, Avital Gilam
  • Functionalized Nanoparticles and Compositions for Cancer Treatment and Methods
    Publication number: 20190142966
    Abstract: Provided herein are functionalized nanoparticles and compositions containing functionalized nanoparticles. The functionalized nanoparticles include a first metal nanoparticle functionalized with a drug and a targeting biomolecule, and a second metal nanoparticle functionalized with an siRNA and a targeting biomolecule. The compositions include the first metal nanoparticle and the second metal nanoparticle. Kits and methods of drug delivery also are provided.
    Type: Application
    Filed: May 11, 2017
    Publication date: May 16, 2019
    Inventors: Natalie Artzi, Joao Conde, Nuria Oliva
  • Hydrogel Particles, Compositions, and Methods
    Publication number: 20170333304
    Abstract: Hydrogel particles are provided that include a crosslinked polymer and a drug conjugated to the crosslinked polymer. The hydrogel particles may include a pH sensitive moiety and a redox sensitive moiety. The hydrogel particles also may be dispersed in a host hydrogel. Kits and methods of drug delivery and treatment also are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Natalie Artzi, Yi Zhang, Nuria Oliva Jorge, Joao Conde
  • Theranostic Nanoprobes for Overcoming Cancer Multidrug Resistance and Methods
    Publication number: 20160243254
    Abstract: Theranostic nanoprobes are provided for overcoming cancer multidrug resistance, and methods for treating biological tissue, including cancerous tissue. The theranostic nanoprobes may include gold nanoparticles functionalized with DNA-hairpin. The DNA-hairpin may be configured to hybridize to a complementary target, which may silence or lessen the multidrug resistance of cancer cells. The theranostic nanoprobes may be configured to release a chemotherapeutic agent upon hybridization of the DNA-hairpin to a target molecule.
    Type: Application
    Filed: February 19, 2016
    Publication date: August 25, 2016
    Inventors: Natalie Artzi, João Conde, Nuria Oliva